OU Portal
Log In
Welcome
Applicants
Z6_60GI02O0O8IDC0QEJUJ26TJDI4
>
Publ3 search
Error:
Javascript is disabled in this browser. This page requires Javascript. Modify your browser's settings to allow Javascript to execute. See your browser's documentation for specific instructions.
{}
Zavřít
Publikační činnost
Probíhá načítání, čekejte prosím...
publicationId :
tempRecordId :
actionDispatchIndex :
navigationBranch :
pageMode :
tabSelected :
isRivValid :
Typ záznamu:
stať ve sborníku (D)
Domácí pracoviště:
Ústav laboratorní medicíny (11430)
Název:
Early diagnosis of invasive candidiasis in intensive care: evaluation of diagnostic biomarkers
Citace
Slepčanová, H., Dobiáš, R., Káňová, M. a Hamal, P. Early diagnosis of invasive candidiasis in intensive care: evaluation of diagnostic biomarkers.
In:
35th Congress of the European Society of Clinical Microbiology and Infectious Diseases: ESCMID Global Abstract Book 2025 2025-04-11 Vienna.
European Society of Clinical Microbiology and Infectious Diseases, 2025. s. 4932-4932. ISSN 2950-5909.
Podnázev
Rok vydání:
2025
Obor:
Počet stran:
1
Strana od:
4932
Strana do:
4932
Forma vydání:
Elektronická verze
Kód ISBN:
neuvedeno
Kód ISSN:
2950-5909
Název sborníku:
ESCMID Global Abstract Book 2025
Sborník:
Mezinárodní
Název nakladatele:
European Society of Clinical Microbiology and Infectious Diseases
Místo vydání:
neuvedeno
Stát vydání:
Sborník vydaný v zahraničí
Název konference:
35th Congress of the European Society of Clinical Microbiology and Infectious Diseases
Místo konání konference:
Vienna
Datum zahájení konference:
Typ akce podle státní
příslušnosti účastníků:
Celosvětová akce
Kód UT WoS:
EID:
Klíčová slova anglicky:
T2MR, invasive candidiasis
Popis v původním jazyce:
BackgroundInvasive candidiasis (IC) remains a major challenge in critically ill patients, requiring rapid and accurate diagnosis to improve patient outcomes. Traditional blood culture methods often fail to detect Candida spp. in the early stages of infection. This study aimed to assess the utility of modern diagnostic biomarkers: T2Candida®, (1,3)-β-D-glucan (BDG), Presepsin (PSEP), and Pentraxin 3 (Ptx3) in differentiating fungal from bacterial infections and improving early IC detection in septic patients.MethodsThis prospective clinical study was conducted at University Hospital Ostrava from May to December 2024. Ten intensive care unit (ICU) patients were enrolled and monitored daily using a panel of biomarkers (BDG, PSEP, Ptx3) in conjunction with molecular (T2Candida®) and microbiological (blood culture) diagnostic methods. Serum BDG was measured using Fungitell®, PSEP was analyzed with Pathfast®, and Ptx3 was assessed via ELISA on the ThunderBolt Analyzer. All biomarker results were correlated with clinical findings, including patient colonization status, intra-abdominal candidiasis (IAC), and bacterial co-infections.ResultsSerum BDG levels exceeding 200 pg/mL and PSEP levels above 700 pg/mL were indicative of probable IC. Ptx3 demonstrated potential as an additional diagnostic marker, with elevated levels correlating with suspected fungal infections. The T2Candida® assay showed limited sensitivity for IAC, detecting Candida spp. in only a small subset of cases. Despite the application of molecular diagnostics, direct blood culture positivity for Candida spp. was rare, aligning with previous findings that candidemia often remains undetected in IAC patients. For detailed biomarker profiles, refer to Biomarker Profiles in Invasive Candidiasis Diagnosis.ConclusionsThe combination of BDG, PSEP, and Ptx3 shows promise for early IC detection, particularly in differentiating fungal from bacterial sepsis. The findings highlight the limitations of T2Candida® in IAC cases and suggest the need for further validation in a larger patient cohort. These preliminary results represent the first phase of an ongoing prospective study, which will continue in 2025 to expand the patient cohort and refine diagnostic algorithms. Future research should focus on optimizing the use of multiple biomarkers to enhance early IC diagnosis and improve antifungal treatment strategies.
Popis v anglickém jazyce:
BackgroundInvasive candidiasis (IC) remains a major challenge in critically ill patients, requiring rapid and accurate diagnosis to improve patient outcomes. Traditional blood culture methods often fail to detect Candida spp. in the early stages of infection. This study aimed to assess the utility of modern diagnostic biomarkers: T2Candida®, (1,3)-β-D-glucan (BDG), Presepsin (PSEP), and Pentraxin 3 (Ptx3) in differentiating fungal from bacterial infections and improving early IC detection in septic patients.MethodsThis prospective clinical study was conducted at University Hospital Ostrava from May to December 2024. Ten intensive care unit (ICU) patients were enrolled and monitored daily using a panel of biomarkers (BDG, PSEP, Ptx3) in conjunction with molecular (T2Candida®) and microbiological (blood culture) diagnostic methods. Serum BDG was measured using Fungitell®, PSEP was analyzed with Pathfast®, and Ptx3 was assessed via ELISA on the ThunderBolt Analyzer. All biomarker results were correlated with clinical findings, including patient colonization status, intra-abdominal candidiasis (IAC), and bacterial co-infections.ResultsSerum BDG levels exceeding 200 pg/mL and PSEP levels above 700 pg/mL were indicative of probable IC. Ptx3 demonstrated potential as an additional diagnostic marker, with elevated levels correlating with suspected fungal infections. The T2Candida® assay showed limited sensitivity for IAC, detecting Candida spp. in only a small subset of cases. Despite the application of molecular diagnostics, direct blood culture positivity for Candida spp. was rare, aligning with previous findings that candidemia often remains undetected in IAC patients. For detailed biomarker profiles, refer to Biomarker Profiles in Invasive Candidiasis Diagnosis.ConclusionsThe combination of BDG, PSEP, and Ptx3 shows promise for early IC detection, particularly in differentiating fungal from bacterial sepsis. The findings highlight the limitations of T2Candida® in IAC cases and suggest the need for further validation in a larger patient cohort. These preliminary results represent the first phase of an ongoing prospective study, which will continue in 2025 to expand the patient cohort and refine diagnostic algorithms. Future research should focus on optimizing the use of multiple biomarkers to enhance early IC diagnosis and improve antifungal treatment strategies.
Seznam ohlasů
Ohlas
R01:
Complementary Content
Deferred Modules
${title}
${badge}
${loading}
Deferred Modules